DeepMed Research

NCIC Clinical Trials Group

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: dexamethasone
Drug: melphalan
Drug: prednisone

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-02

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 595

Registration Number: NCT00002678

Locations: 🇨🇦
Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦
William Osler Health Centre, Brampton, Ontario, Canada
🇨🇦
Credit Valley Hospital, Mississauga, Ontario, Canada

and more 34 locations

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: buserelin
Drug: flutamide
Drug: goserelin
Drug: leuprolide acetate
Drug: nilutamide
Procedure: orchiectomy
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-03

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 361

Registration Number: NCT00002633

Locations: 🇨🇦
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada

and more 12 locations

Radiation or Observation Only in Endometrial Cancer Who Have Undergone Surgery

Not Applicable

Completed

Conditions: Endometrial Cancer

Interventions: Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-06

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 116

Registration Number: NCT00002807

Locations: 🇨🇦
Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
Newfoundland Cancer Treatment and Research Foundation, St. Johns, Newfoundland and Labrador, Canada

and more 22 locations

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

Phase 3

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: gemcitabine hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-02

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 569

Registration Number: NCT00026338

Locations: 🇧🇷
Hospital Israelita Albert Einstein, Sao Paulo, Brazil
🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸
Loma Linda University Cancer Institute, Loma Linda, California, United States

and more 168 locations

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: buserelin
Drug: cyproterone acetate
Drug: flutamide
Drug: goserelin
Drug: leuprolide acetate
Drug: nilutamide

First Posted Date: 2003-01-27

Last Posted Date: 2021-06-23

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 1386

Registration Number: NCT00003653

Locations: 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦
BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦
Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada

and more 26 locations

Bortezomib in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 30

Registration Number: NCT00030875

Locations: 🇨🇦
Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 7 locations

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Biological: epoetin alfa
Drug: epirubicin hydrochloride
Biological: filgrastim
Drug: doxorubicin hydrochloride
Drug: fluorouracil
Drug: paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-05

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 2104

Registration Number: NCT00014222

Locations: 🇺🇸
Sparks-Arkansas Oklahoma Cancer Treatment Centre, Fort Smith, Arkansas, United States
🇺🇸
Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States

and more 75 locations

Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-06

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 128

Registration Number: NCT00049075

Locations: 🇨🇦
Providence Health Care - Vancouver, Vancouver, British Columbia, Canada
🇨🇦
Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦
Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada

and more 31 locations

Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

Interventions: Drug: carboplatin
Drug: cisplatin
Drug: paclitaxel
Drug: topotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-02

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 819

Registration Number: NCT00028743

Locations: 🇨🇦
Lions Gate Hospital, North Vancouver, British Columbia, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada

and more 25 locations

SarCNU in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-09

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 18

Registration Number: NCT00028015

Locations: 🇨🇦
Kingston Regional Cancer Centre, Kingston, Ontario, Canada
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy